Reewarm PTX 药物球囊扩张导管

Search documents
心脉医疗: 心脉医疗:2025年半年度业绩预告的自愿性披露公告
Zheng Quan Zhi Xing· 2025-07-14 09:20
Performance Forecast - The company expects to achieve operating revenue between 708.46 million and 787.17 million yuan in the first half of 2025, representing a decrease of 78.72 million yuan to 0.00 million yuan compared to the same period last year, which is a year-on-year decline of 10.00% to 0.00% [1] - The net profit attributable to the parent company is projected to be between 303.54 million yuan and an unspecified amount, reflecting a year-on-year decrease of 24.78% to 10.52% [1] Previous Year Performance - The previous year's net profit was 403.52 million yuan [1] Reasons for Performance Changes - The company’s innovative products, including the Castor branched aortic stent graft and Minos abdominal aortic stent graft, have shown strong growth in clinical applications and implant volumes. However, market environment changes in the second half of 2024, along with adjustments in product pricing and promotion strategies, are expected to impact sales growth and profits in the first half of 2025 [1] Product Approvals and Achievements - The company has received approval for several products, including the Hector multi-branch aortic stent graft system, which is now in the special review process by the National Medical Products Administration (NMPA) [2] - The company was awarded the "2024 Advanced Manufacturing Outstanding Contribution Award" in Pudong New District, and its core product, the Castor branched aortic stent, received the 25th China Patent Gold Award [2] Market Presence - The company’s products are currently in clinical use in over 2,700 hospitals across 31 provinces, autonomous regions, municipalities, and Hong Kong and Macau, with international business extending to over 40 countries and regions [3] - The Minos abdominal aortic stent graft and Hercules balloon dilation catheter have successfully obtained EU CE MDR certification [3] Future Plans - The company plans to continue increasing foreign investments and deepen its global layout to provide high-quality medical device products and services to patients worldwide [3]